HC Wainwright Reaffirms Buy Rating for Theravance Biopharma (NASDAQ:TBPH)

HC Wainwright reaffirmed their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a report published on Monday morning, Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock.

TBPH has been the topic of a number of other research reports. StockNews.com lowered shares of Theravance Biopharma from a buy rating to a hold rating in a research note on Saturday, August 10th. TD Cowen reduced their target price on Theravance Biopharma from $10.00 to $9.00 and set a hold rating on the stock in a report on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an outperform rating to a market perform rating and lowered their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, Leerink Partnrs cut Theravance Biopharma from a strong-buy rating to a hold rating in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Hold and a consensus price target of $13.75.

Theravance Biopharma Stock Up 0.4 %

TBPH stock opened at $8.27 on Monday. The stock’s 50 day moving average is $8.75 and its two-hundred day moving average is $8.87. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71. The company has a market capitalization of $402.19 million, a PE ratio of -9.62 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The company had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter last year, the firm posted ($0.28) EPS. As a group, sell-side analysts anticipate that Theravance Biopharma will post -1.04 EPS for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Eli Samaha purchased 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new position in Theravance Biopharma during the 2nd quarter worth $986,000. Marshall Wace LLP raised its stake in shares of Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after purchasing an additional 135,426 shares in the last quarter. Bank of Montreal Can lifted its holdings in Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares during the period. XTX Topco Ltd bought a new position in Theravance Biopharma in the 2nd quarter valued at about $129,000. Finally, Hsbc Holdings PLC bought a new position in Theravance Biopharma in the 2nd quarter valued at about $108,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.